Medicare Will Only Cover Aduhelm for Alzheimer’s Patients in Clinical Trials
Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer’s patients enrolled in clinical trials of the drug.
Approved amid controversy last year by the U.S. Food and Drug Administration, the latest decision was meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking, according to officials with the U.S. Centers for Medicare and Medicaid Services (CMS).
Retiree News 
Comments are closed.